Meridian Bioscience, Inc.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates thro…
Medical - Diagnostics & Research
US, Cincinnati [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -61.64 | -57.13 | 148.95 | |
| Graham Fair Price | 119.18 | 10.89 | 4.97 | |
| PEG | -94.27 | 0.02 | 0.34 | |
| Price/Book | 14.22 | 4.28 | 3.75 | |
| Price/Cash Flow | 68.53 | -291.38 | -925.78 | |
| Prices/Earnings | -79.78 | -12.22 | 60.45 | |
| Price/Sales | 21.98 | 25.62 | 21.00 | |
| Price/FCF | 68.53 | -291.38 | -925.78 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 6.97 | 0.55 | 0.52 | |
| Operating Margin | 598.14 | -0.49 | 0.07 | |
| ROA | 429.97 | -0.07 | 0.01 | |
| ROE | 0.02 | -0.09 | 464.96 | |
| ROIC | 0.02 | -0.10 | 383.38 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | -0.03 | -77.53 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 1.70 | -7.05 | 315.69 | |
| EPS QOQ | 1.76 | -6.23 | 253.08 | |
| FCF QOQ | -1.12 | -2.36 | -110.56 | |
| Revenue QOQ | -0.03 | -0.13 | -331.92 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 192.64 | 257.50 | 33.67 | |
| Days Sales Outstanding (DSO) | 262.52 | 266.67 | 1.58 | |
| Inventory Turnover | 0.47 | 0.35 | -25.19 | |
| Debt/Capitalization | 0.08 | 0.08 | 7.99 | |
| Quick Ratio | 2.22 | 1.47 | -33.71 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 8.41 | 7.76 | -7.79 | |
| Cash | 1.86 | 1.69 | -9.33 | |
| Capex | -0.08 | -0.06 | 23.93 | |
| Free Cash Flow | -0.03 | -0.11 | -234.65 | |
| Revenue | 1.50 | 1.30 | -13.65 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad